Seek Labs Expands Oncology Research for Sequence Ablation Therapeutics with Up to $3 Million in Foundation Support
Two2Ten Foundation supports the continued development of Seek Labs’ Sequence Ablation Therapeutics (SAT) platform into oncology, honoring the memory of Travis Snyder SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) — Seek Labs, a Salt Lake City Tech Bio company developing programmable CRISPR-based medicines, today announced an agreement with the Two2Ten Foundation providing up to […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.